PDCD1 and non-small cell lung carcinoma: Our findings indicate that the addition of abnobaViscum® therapy is significantly associated with enhanced survival in patients being diagnosed with advanced or metastatic NSCLC receiving standard PD-1/PD-L1 inhibitor therapy, regardless of age, gender, metastatic status, or oncological treatment regimen (see summative Figure 4).